

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Sellinger, Philip

US Attorney, Department of Justice - Executive Office for United States Attorneys

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Sellinger, Philip [electronically signed on 02/10/2022 by Sellinger, Philip in Integrity.gov] - Filer received a 20 day filing extension.

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Sarah Wasserbly, for James E. Macklin, Certifying Official [electronically signed on 06/01/2022 by Sarah Wasserbly, for James E. Macklin in Integrity.gov]

Other review conducted by

/s/ SADLOWSKI, CAROLINE, Ethics Official [electronically signed on 05/31/2022 by SADLOWSKI, CAROLINE in Integrity.gov]

U.S. Office of Government Ethics Certification

/s/ Granahan, Megan, Certifying Official [electronically signed on 06/27/2022 by Granahan, Megan in Integrity.gov]

Data Revised - Workflow re-designation - 05/31/2022

Data Revised 02/17/2022

Data Revised 02/11/2022

Data Revised 02/10/2022

Transactions

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	Cue Biopharma, Inc. (CUE)	Sale	01/27/2022	No	\$1,001 - \$15,000
2	Provention Bio, Inc. (PRVB)	Sale	01/27/2022	No	\$1,001 - \$15,000
3	Taysha Gene Therapies Inc (TSHA)	Sale	01/27/2022	No	\$1,001 - \$15,000
4	TFF Pharmaceuticals Inc (TFFP)	Sale	01/27/2022	No	\$1,001 - \$15,000
5	Aptose Biosciences Inc (APTO)	Purchase	01/26/2022	No	\$1,001 - \$15,000
6	Ocugen Inc (OCGN)	Sale	01/26/2022	No	\$1,001 - \$15,000
7	Taysha Gene Therapies Inc (TSHA)	Sale	01/26/2022	No	\$1,001 - \$15,000
8	TFF Pharmaceuticals Inc (TFFP)	Sale	01/26/2022	No	\$1,001 - \$15,000
9	Sorrento Therapeutics, Inc. (SRNE)	Sale	01/24/2022	No	\$1,001 - \$15,000
10	Aptose Biosciences Inc (APTO)	Purchase	01/21/2022	No	\$1,001 - \$15,000
11	Enphase Energy, Inc. (ENPH)	Purchase	01/21/2022	No	\$15,001 - \$50,000
12	SolarEdge Technologies, Inc. (SEDG)	Purchase	01/21/2022	No	\$15,001 - \$50,000
13	Aptose Biosciences Inc (APTO)	Purchase	01/20/2022	No	\$1,001 - \$15,000
14	Ocugen Inc (OCGN)	Sale	01/20/2022	No	\$1,001 - \$15,000
15	Sorrento Therapeutics, Inc. (SRNE)	Sale	01/20/2022	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
16	Ocugen Inc (OCGN)	Sale	01/19/2022	No	\$1,001 - \$15,000
17	Sorrento Therapeutics, Inc. (SRNE)	Sale	01/19/2022	No	\$1,001 - \$15,000
18	Aptose Biosciences Inc (APTO)	Purchase	01/18/2022	No	\$1,001 - \$15,000
19	enVVeno Medical Corp (NVNO)	Purchase	01/18/2022	No	\$1,001 - \$15,000
20	QRHC	Purchase	01/18/2022	No	\$1,001 - \$15,000
21	enVVeno Medical Corp (NVNO)	Purchase	01/14/2022	No	\$1,001 - \$15,000
22	Intellia Therapeutics, Inc. (NTLA)	Purchase	01/13/2022	No	\$15,001 - \$50,000
23	SPDR S&P Biotech ETF (XBI)	Sale	01/13/2022	No	\$1,001 - \$15,000
24	TFF Pharmaceuticals Inc (TFFP)	Purchase	01/12/2022	No	\$1,001 - \$15,000
25	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/11/2022	No	\$1,001 - \$15,000
26	Intellia Therapeutics, Inc. (NTLA)	Purchase	01/11/2022	No	\$1,001 - \$15,000
27	TFF Pharmaceuticals Inc (TFFP)	Purchase	01/11/2022	No	\$1,001 - \$15,000
28	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Purchase	01/10/2022	No	\$1,001 - \$15,000
29	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/07/2022	No	\$15,001 - \$50,000
30	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/06/2022	No	\$15,001 - \$50,000
31	Aptose Biosciences Inc (APTO)	Purchase	01/05/2022	No	\$1,001 - \$15,000
32	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/05/2022	No	\$1,001 - \$15,000
33	Intellia Therapeutics, Inc. (NTLA)	Purchase	01/05/2022	No	\$15,001 - \$50,000
34	Krystal Biotech, Inc. (KRYS)	Purchase	01/05/2022	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
35	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/04/2022	No	\$1,001 - \$15,000
36	Intellia Therapeutics, Inc. (NTLA)	Purchase	01/04/2022	No	\$1,001 - \$15,000
37	Krystal Biotech, Inc. (KRYB)	Purchase	01/04/2022	No	\$1,001 - \$15,000
38	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	01/03/2022	No	\$1,001 - \$15,000
39	Intellia Therapeutics, Inc. (NTLA)	Purchase	01/03/2022	No	\$1,001 - \$15,000
40	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/31/2021	No	\$1,001 - \$15,000
41	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/30/2021	No	\$1,001 - \$15,000
42	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/29/2021	No	\$1,001 - \$15,000
43	Intellia Therapeutics, Inc. (NTLA)	Purchase	12/29/2021	No	\$1,001 - \$15,000
44	Cue Biopharma, Inc. (CUE)	Purchase	12/28/2021	No	\$1,001 - \$15,000
45	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/28/2021	No	\$1,001 - \$15,000
46	Intellia Therapeutics, Inc. (NTLA)	Purchase	12/28/2021	No	\$1,001 - \$15,000
47	Quest Resource Holding Corp (QRHC)	Purchase	12/28/2021	No	\$1,001 - \$15,000
48	Taysha Gene Therapies Inc (TSHA)	Purchase	12/28/2021	No	\$1,001 - \$15,000
49	TFF Pharmaceuticals Inc (TFFP)	Purchase	12/28/2021	No	\$1,001 - \$15,000
50	Uniqure NV (QURE)	Sale	12/28/2021	No	\$1,001 - \$15,000
51	Cue Biopharma, Inc. (CUE)	Purchase	12/27/2021	No	\$1,001 - \$15,000
52	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/27/2021	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
53	Intellia Therapeutics, Inc. (NTLA)	Purchase	12/27/2021	No	\$1,001 - \$15,000
54	Krystal Biotech, Inc. (KRYS)	Purchase	12/27/2021	No	\$1,001 - \$15,000
55	Quest Resource Holding Corp (QRHC)	Purchase	12/27/2021	No	\$1,001 - \$15,000
56	Taysha Gene Therapies Inc (TSHA)	Purchase	12/27/2021	No	\$1,001 - \$15,000
57	TFF Pharmaceuticals Inc (TFFP)	Purchase	12/27/2021	No	\$1,001 - \$15,000
58	Uniqure NV (QURE)	Sale	12/27/2021	No	\$1,001 - \$15,000
59	Cue Biopharma, Inc. (CUE)	Purchase	12/23/2021	No	\$1,001 - \$15,000
60	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/23/2021	No	\$1,001 - \$15,000
61	Taysha Gene Therapies Inc (TSHA)	Purchase	12/23/2021	No	\$1,001 - \$15,000
62	Cue Biopharma, Inc. (CUE)	Purchase	12/22/2021	No	\$1,001 - \$15,000
63	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Sale	12/22/2021	No	\$1,001 - \$15,000
64	Intellia Therapeutics, Inc. (NTLA)	Purchase	12/22/2021	No	\$15,001 - \$50,000
65	Krystal Biotech, Inc. (KRYS)	Purchase	12/22/2021	No	\$1,001 - \$15,000
66	Taysha Gene Therapies Inc (TSHA)	Purchase	12/22/2021	No	\$1,001 - \$15,000
67	TFF Pharmaceuticals Inc (TFFP)	Purchase	12/22/2021	No	\$1,001 - \$15,000
68	Cassava Sciences, Inc. (SAVA)	Sale	12/21/2021	No	\$1,001 - \$15,000
69	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Purchase	12/21/2021	No	\$15,001 - \$50,000
70	Taysha Gene Therapies Inc (TSHA)	Purchase	12/21/2021	No	\$1,001 - \$15,000
71	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Purchase	12/20/2021	No	\$1,001 - \$15,000

#	DESCRIPTION	TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
72	Cue Biopharma, Inc. (CUE)	Purchase	12/17/2021	No	\$1,001 - \$15,000
73	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Purchase	12/17/2021	No	\$15,001 - \$50,000
74	Uniqure NV (QURE)	Sale	12/17/2021	No	\$1,001 - \$15,000
75	GS FINANCIAL SQUARE FEDERAL INSTRUMENTS MUTUAL FUND	Purchase	12/16/2021	No	\$1,001 - \$15,000
76	Krystal Biotech, Inc. (KRYB)	Purchase	12/16/2021	No	\$1,001 - \$15,000
77	Lantern Pharma Inc (LTRN)	Sale	12/16/2021	No	\$1,001 - \$15,000
78	Uniqure NV (QURE)	Sale	12/16/2021	No	\$1,001 - \$15,000

Endnotes

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget

during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13770 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.
